T1397 A Novel, Oral 5HT3 Partial Agonist, DDP733, Improves Overall Response in Patients with Irritable Bowel Syndrome and Constipation (IBS-c): A Randomized, Double Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study

Paterson, William G.; Ford, David C.; Ganguli, Sujata; Rеynolds, Robert; Pliamm, Lew; O’Mahony, Michael; Paré, Pierre; Nurbhai, Suhail; Feagan, Brian; Landau, Steven B.

doi:10.1016/s0016-5085(08)62551-2

Cited by 10 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two newer compounds, a selective 5-HT3R antagonist (DPP-733) and a combined norepinephrine (NE) reuptake inhibitor and 5-HT3R antagonist (NARI) have been evaluated in small clinical trials. 25 …”

Section: -Ht3-receptor Antagonistsmentioning

confidence: 99%

Current state of pharmacology and therapeutics in irritable bowel syndrome with special reference to brain-gut axis

Mishra

Singh

Pandey

2013

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS), principal morbidity being visceral hypersensitivity, consumes significant speciality gastroenterologic and general practitioner’s care. The complex etiology perhaps varying among the patients makes therapeutic address very challenging. Continuous researches on neurophysiological aberrations in IBS have continued. The drugs and the neurophysiological understanding with regard to addressing visceral hypersensitivity are relevant to be appraised. The translation of research wisdom into clinical practice may be facilitated by gastroenterology experts. The issues of effectiveness of the options in general and in particular patients may thus be addressed. [Int J Basic Clin Pharmacol 2013; 2(2.000): 122-129

show abstract

Section: -Ht3-receptor Antagonistsmentioning

confidence: 99%

Current state of pharmacology and therapeutics in irritable bowel syndrome with special reference to brain-gut axis

Mishra

Singh

Pandey

2013

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

show abstract

“…5-HT 3 receptor partial agonists 5-Hydroxytryptophan (5-HT) acts on GPCRs within the GI tract to modulate gut motility in either a pro-or antipropulsive manner, depending on the GPCR subtype and its anatomical location [4]. Pumosetrag, 1, a 5-HT 3 partial agonist, has been shown to be moderately efficacious in promoting bowel motility in a small study of patients with constipation and has shown improvements in ''overall response'' in IBS-C patients, yet its development for these indications was reported to have been discontinued [5][6][7]. Nevertheless, in late 2010, it was reported that recruitment for a Phase 2 trial in GERD had begun [8]; no other 5-HT 3 agonists appear to be in active clinical studies for GI indications.…”

Section: Key Clinical Developmentsmentioning

confidence: 99%

Developments and Advances in Gastrointestinal Prokinetic Agents

Dale¹,

Hollingworth²,

McKenna³

2011

Annual Reports in Medicinal Chemistry

View full text Add to dashboard Cite

“…This is an important issue because the drug can have less systemic side effects compared with other serotonin modulators [Evangelista, 2007]. In a randomized, double-blind, placebo-controlled doseranging study, pumosetrag was administered three times per day for 28 days in four treatment groups: 0.2, 0.5, 0.8 and 1.4 mg. Trial results demonstrated favorable effects in 53.8% of subjects with the 1.4 mg dose compared with 15.4% of subjects in the placebo group [Paterson, 2008a]. Adverse events occurred with similar frequency in all treatment groups and the majority were mild or moderate.…”

Section: -Ht3 Modulatorsmentioning

confidence: 99%

Review: Therapeutic advances in functional gastrointestinal disease: irritable bowel syndrome

Gaman

Bucur

Kuo

2009

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Reported prevalence rates of irritable bowel syndrome (IBS) are between 8% to 20% in the US general population with an average medical expenditure of US$1.35 billion direct and US$205 million indirect costs. Current pathophysiologic theories are based on abnormalities of both the brain and gut, thus setting a new stage for current and future therapeutic approaches. There are numerous treatment options in IBS acting centrally and peripherally by influencing motility and visceral sensitivity. Clinical evidence is variable; however, newer emerging treatments are being evaluated using better-designed clinical trials. Accurate assessment of IBS drug efficacy is still hampered by heterogeneity of the IBS population. Novel methods such as pharmacogenomics or brain imaging may be helpful in the future to better understand and characterize IBS patient subtypes, and this in turn will lead to more specific and efficient therapeutic options. Patient subpopulation measurement of side effects is also a clinical challenge and further understanding could improve treatment efficacy by enhancing the patient compliance.

show abstract

T1397 A Novel, Oral 5HT3 Partial Agonist, DDP733, Improves Overall Response in Patients with Irritable Bowel Syndrome and Constipation (IBS-c): A Randomized, Double Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study

Cited by 10 publications

References 0 publications

Current state of pharmacology and therapeutics in irritable bowel syndrome with special reference to brain-gut axis

Current state of pharmacology and therapeutics in irritable bowel syndrome with special reference to brain-gut axis

Developments and Advances in Gastrointestinal Prokinetic Agents

Review: Therapeutic advances in functional gastrointestinal disease: irritable bowel syndrome

Contact Info

Product

Resources

About